Spave Science

Spave Science is a pre-clinical stage biopharmaceutical company dedicated to developing breakthrough medications for central nervous system (CNS) disorders, with an initial focus on Parkinson's disease, amyotrophic lateral sclerosis (ALS), and depression. The company's lead asset, SPV-400, is a novel small-molecule tropomyosin receptor kinase B (TrkB) agonist designed to directly activate the TrkB receptor and overcome the target delivery limitations of brain-derived neurotrophic factor (BDNF). By modulating neuronal signaling and biological pathways, Spave Science aims to save neuronal cells from damage and degeneration, support neuroplasticity, and improve cell survival. Led by experienced neurologists and pharmaceutical executives, the company is committed to accelerating the translation of scientific discoveries into transformative therapies for patients with serious nervous system disorders.